Biomarkers

P009 - Effect Of Interferon β-1a Treatment On Serum Neurofilament Light-chain Levels In Patients With A First Clinical Demyelinating Event In The REFLEX Trial

Presenter
  • M. Freedman
Author
  • J. Kuhle
  • D. Leppert
  • G. Comi
  • N. De Stefano
  • L. Kappos
  • M. Freedman
  • S. Roy
  • D. Issard
Session Title
Poster Session 1 / Opening Networking Event

Previous ePoster
P008 - Differential Expression Of Gene Splice Variants In Macrophages From Multiple Sclerosis Patients In An Underrepresented Minority Population

Next ePoster
P010 - Gd+ Lesions Impacts On The Association Between Age And Serum Neurofilament Light In Patients With Multiple Sclerosis
P011 - Higher Sensitivity Of Quantitative RT-PCR Compared With Flow Cytometry For Quantification Of B Cells After Anti-CD20 Monoclonal Antibody Therapy
No Preview Available
P013 - Metabolic Network Alterations In Multiple Sclerosis And Correlation With Disease Severity
P014 - Multi-layer Analysis Of Quantitative 7t Mri In The Cortex Of Multiple Sclerosis Patients Reveals Pathology Associated With Disability
P015 - Multivariate Protein Biomarker Models Better Predict Multiple Sclerosis Radiographic Disease Activity Compared To Serum Levels Of Nfl Alone
No Preview Available
P016 - No Effect Of Body Mass Index On Serum Neurofilament Light In Long Term Rituximab Treated Multiple Sclerosis Patients: The Need To Correct For Age, Blood Volume, And Disability
P017 - Serum Neurofilament Light Chain Levels as an Indicator of Treatment Response in CARE-MS I Patients
P018 - Serum Nfl Levels In First Five Years Correlate With 10-year Deep Gray Matter MRI Volumes In Multiple Sclerosis
P019 - Evaluation Of Evidence From Smart Phone Sensors And Patient-reported Outcomes In Persons With Multiple Sclerosis (ElevateMS)
P020 - Muscle Fatigue In People With Multiple Sclerosis Impairs Standing Balance